Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Oncternal Therapeutics Inc ONCT

Healthcare Biotechnology
Oncternal Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development of oncology therapies for the treatment of patients with cancers that have critical unmet medical needs. The Company’s product candidates include ONCT-534, ONCT-808, Zilovertamab, and ONCT-216. ONCT-534 is a dual-action androgen receptor inhibitor (DAARI), for the treatment of... see more

Recent & Breaking News (NDAQ:ONCT)

Oncternal Therapeutics to Provide Business Update and Report Third Quarter 2021 Financial Results

GlobeNewswire October 29, 2021

Oncternal Therapeutics Announced Pre-Clinical Data from ONCT-534, an Androgen Receptor N-Terminal-Domain-Binding Small Molecule Degrader, Was Accepted for Virtual Poster Presentation at AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics

GlobeNewswire October 5, 2021

Oncternal Therapeutics Reports Granting of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire October 1, 2021

Oncternal Therapeutics and Celularity Enter into Research Collaboration to Evaluate Targeted Placental-Derived Cellular Therapies

GlobeNewswire September 20, 2021

Celularity and Oncternal Therapeutics Enter into Research Collaboration to Evaluate Targeted Placental-Derived Cellular Therapies

GlobeNewswire September 20, 2021

Oncternal Therapeutics to Participate in September Investor Conferences

GlobeNewswire September 9, 2021

Oncternal Therapeutics Rounds Out Leadership Team with Appointment of Steven Hamburger, Ph.D. as Senior Vice President, Regulatory Affairs and Quality Assurance

GlobeNewswire September 1, 2021

Oncternal Provides Business Update and Announces Second Quarter 2021 Financial Results

GlobeNewswire August 5, 2021

Oncternal Therapeutics Reports Granting of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire August 2, 2021

Oncternal Therapeutics to Participate in the BTIG Virtual Biotechnology Conference

GlobeNewswire August 2, 2021

Oncternal Therapeutics to Provide Business Update and Report Second Quarter 2021 Financial Results

GlobeNewswire July 29, 2021

Oncternal Therapeutics Appoints Pablo Urbaneja as Sr. Vice President, Corporate Development

GlobeNewswire July 1, 2021

Oncternal Therapeutics Reports Granting of Inducement Award Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire June 1, 2021

Oncternal Therapeutics to Participate in Jefferies Virtual Healthcare Conference

GlobeNewswire May 26, 2021

Oncternal Therapeutics Presents Updated Interim Data for TK216 in Patients with Relapsed or Refractory Ewing Sarcoma in an Oral Session at ASCO 2021

GlobeNewswire May 19, 2021

Oncternal Therapeutics Presents Updated Interim Data for Cirmtuzumab in Combination with Ibrutinib at ASCO 2021

GlobeNewswire May 19, 2021

Oncternal Therapeutics Announces Appointment of Salim Yazji as Chief Medical Officer

GlobeNewswire May 17, 2021

Oncternal Provides Business Update and Announces First Quarter 2021 Financial Results

GlobeNewswire May 6, 2021

Oncternal Therapeutics Reports Granting of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire May 3, 2021

Oncternal Therapeutics to Report First Quarter 2021 Financial Results and Provide Business Update

GlobeNewswire April 29, 2021